Mekonos is a company that has created a platform that allows cell and gene therapies to be more accessible. The company was founded by Anil Narsimha, Greg Sitters, and Steven Banerjee in 2017, in San Francisco, California, United States.
Mekonos is responsible for developing over nine hundred therapeutic candidates, and expect roughly forty of them to be approved by the end of 2022. They developed their therapeutics through their platform solution, Iris, which is a System-on-a-Chip that allows for automated deliveries and precision for multiplexing.
Iris is a pharmaceutical and biotechnological platform that allows for targeted delivery and dose control of gene therapeutics that includes nucleic acids, protein complexes, and small molecules, and cell treatments such as primary, immune, and stem cells.
Microfluidics, micro-electro-mechanical systems, and chemistry to expand their catalogue of payloads and cell types. Their various methods of expansion allows Mekonos to scale their silicon technology for drug discover and development.
Antony van Hoorn
Meng Ting Chung